A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-Week Results

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 494-497

  Elion, Richard ^a   Molina, Jean Michel ^b   Ramón Arribas López, José ^c   Cooper, David ^d   Maggiolo, Franco ^e   Wilkins, Edmund ^f   Conway, Brian ^g   Liu, Ya Pei ^h   Margot, Nicolas ^h   Rhee, Martin ^h   Chuck, Steven L ^h   Szwarcberg, Javier ^h  

^a WhitmanWalker GMHW Clinic   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e OSPEDALI RIUNITI   (Italy)

^f NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^g VANCOUVER INFECTIOUS DISEASES CENTRE   (Canada)

^h GILEAD SCIENCES   (United States)

Author keywords

Efficacy; Elvitegravir; HIV 1; Raltegravir; Safety

Indexed keywords

ANTIDIARRHEAL AGENT; DARUNAVIR; DIAMORPHINE; ELVITEGRAVIR; PROTEINASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS RNA;

AIRWAY OBSTRUCTION; ARTHRALGIA; BACKACHE; BRONCHITIS; CARDIOMEGALY; CAUSE OF DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTOXICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FOLLOW UP; GENOTYPE; HEART ARREST; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MITRAL VALVE PROLAPSE; MORTALITY; MUTATION; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SEPSIS; SIDE EFFECT; SINUSITIS; TRAFFIC ACCIDENT; URINARY TRACT INFECTION;

DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LONGITUDINAL STUDIES; PYRROLIDINONES; QUINOLONES; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 84880204551     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318298469c     Document Type: Conference Paper

References (8)

1. Shimura K, Kodama E, Sakagami, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82:764-774.
2. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5.
3. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a oncedaily integrase inhibitor, against resistant HIV type 1:results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;20:814-822.
4. Mathias AA, West S, Hui J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009; 85:64-70.
5. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, doubleblind, phase 3, non-inferiority study. Lancet Infect Dis. 2012;12:27-35.
6. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inform J. 2011;45:291-300.
7. Margot NA, Rhee MS, Szwarcberg JS, et al. Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-US-183-0145. Paper presented at:XIX International AIDS Conference; July 2012; Washington, DC.
8. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drug-resistant HIV infection:week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50:605-612.